Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN1 | Q05586 | 6/20 | 0.71 |
| ▸ | GRIN2B | Q13224 | 6/20 | 0.71 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | NPY1R | P25929 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13656132 | 0.87 | GRIN1 (0.67) | GRIN1GRIN2BALDH1A1HPGD | |
| SCHEMBL12575950 | 0.86 | GRIN1 (0.77) | GRIN1GRIN2BNPC1USP2ALDH1A1 | |
| SCHEMBL13656205 | 0.85 | GRIN1 (0.52) | GRIN1GRIN2BMEN1KMT2AMAPT | |
| SCHEMBL13656111 | 0.85 | GRIN1 (0.67) | GRIN1GRIN2BALDH1A1MEN1KMT2A | |
| SCHEMBL2022077 | 0.83 | GRIN1 (1.00) | GRIN1GRIN2BNPC1USP2ALDH1A1 | |
| SCHEMBL13656207 | 0.82 | GRIN1 (0.69) | GRIN1GRIN2BALDH1A1HTT | |
| SCHEMBL13656130 | 0.77 | GRIN1 (0.69) | GRIN1GRIN2BNPC1USP2ALDH1A1 | |
| SCHEMBL13656210 | 0.74 | KMT2A (0.56) | GRIN1GRIN2BALDH1A1MEN1KMT2A | |
| SCHEMBL13656202 | 0.73 | GRIN1 (0.49) | GRIN1GRIN2BALDH1A1HPGDMEN1 | |
| SCHEMBL12575509 | 0.71 | GRIN1 (0.76) | GRIN1GRIN2BALDH1A1HPGDMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8420680-B2 | NMDA receptor antagonists for neuroprotection | EMORY UNIVERSITY (US) | 2013-04-16 | — | — | US | disclosed |
| US-20090253710-A1 | NMDA Receptor Antagonists for Neuroprotection | EMORY UNIVERSITY | 2009-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253710-A1 | NMDA Receptor Antagonists for Neuroprotection | GRIN1, GRIN2C, GRIK1 | GRIN1 1/4885GRIN2B 7/4885NPC1 1480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.